These analyses confirmed that the expression of these metabolic genes was indeed reduced in Dox-treated TTP + tdTom-expressing PC-3 cells compared to Dox-treated tdTom-expressing PC-3 cells (Figure 8); however, RNA immunoprecipitation studies must be performed to prove that TTP directly binds to and regulates these mRNAs in prostate cancer cells. The gene discussed is ZFP36; the disease is prostate carcinoma.